Overview
Parabacteroides distasonis is an obligately anaerobic, Gram-negative, non-spore-forming bacterium belonging to the phylum Bacteroidota (formerly Bacteroidetes). It is a core member of the healthy human gut microbiome, enriched in individuals with balanced metabolic profiles. Research suggests that P. distasonis may play a significant role in bile acid metabolism, immune regulation, and protection against metabolic disorders including obesity and insulin resistance.
Classification
P. distasonis was originally classified within the genus Bacteroides before being reclassified into the genus Parabacteroides. It belongs to the family Tannerellaceae within the order Bacteroidales. As a member of the Bacteroidota phylum, it shares ecological niches with related organisms such as Bacteroides fragilis and Bacteroides thetaiotaomicron, though it occupies a distinct phylogenetic lineage with unique metabolic capabilities.
Key Characteristics
P. distasonis is notable for its capacity to regulate the bile acid pool, converting cholic acid to 3-acetylcholic acid and modulating nucleotide metabolism including uracil and purine pathways. Human-derived strains have demonstrated antimicrobial activity against clinically relevant pathogens such as Acinetobacter baumannii (23.78% growth inhibition) and Salmonella enteritidis (33.65%). Additionally, strains have shown anti-inflammatory capacity by reducing nitric oxide production by up to 75% in LPS-stimulated macrophages, along with antioxidant activity (35-51% DPPH inhibition) and bile and acid tolerance confirming gastrointestinal survival.
Health Significance
Preclinical studies suggest that P. distasonis may provide broad metabolic protection. Its administration has been associated with attenuated obesity, enhanced insulin sensitivity, and improved bile acid and short-chain fatty acid metabolism in animal models. Notably, synergistic effects with Akkermansia muciniphila have been demonstrated in protecting against colitis, where the combination improved intestinal epithelial integrity and restored healthy microbiota composition. Research also points to potential roles in colorectal cancer protection and hepatic fibrosis prevention. However, rare reports of IBD exacerbation exist, suggesting that effects may be context-dependent in certain individuals. Clinical trials in humans are needed to confirm these promising preclinical findings.